EGFR and adenocarcinoma: In 102 patients with uncommon EGFR mutations, multivariate analysis indicated that patients with a concomitant common EGFR mutation (19del/L858R) were associated with longer PFS (p = 0.003, HR 0.500, 95% CI: 0.315–0.792), while patients with non-adenocarcinoma and poor ECOG PS score were associated with shorter PFS (p = 0.004, HR 3.221, 95% CI 1.447–7.168; and p = 0.005, HR 2.111, 95% CI 1.258–3.541, respectively) (Table 4).